Pub Date : 2025-06-01DOI: 10.1016/j.reumae.2025.501899
Luis Javier Cajas , Julia Recalde Reyes , Javier Alejandro Correa , Wilder Carvajal , Carolina Torres , José S. Cortés
Introduction
This study investigated the association between high-altitude residence (>2500 m above sea level) and the presence of high probability of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc).
Methods
A retrospective case–control study was conducted with 368 patients diagnosed with SSc at the rheumatology outpatient clinic of a university hospital in Bogotá, Colombia. Patients were divided into two groups based on the presence of high probability of PH. Clinical, demographic, and high-altitude residence data were collected and analyzed. A multiple logistic regression model was used to control confounding variables.
Results
Patients residing at high altitudes had a significantly greater risk of presenting high probability of PH than those living at lower altitudes did (odds ratio: 2.0). Other significant factors included the diffuse cutaneous subtype of SSc and the presence of interstitial lung disease.
Discussion
High-altitude residence is a potential risk factor for presenting high probability of PH in SSc patients, warranting closer monitoring and tailored management in these populations. Further studies are warranted to confirm these findings.
{"title":"Residence at high altitude as a risk factor for high probability of pulmonary hypertension in patients with systemic sclerosis: A case–control study","authors":"Luis Javier Cajas , Julia Recalde Reyes , Javier Alejandro Correa , Wilder Carvajal , Carolina Torres , José S. Cortés","doi":"10.1016/j.reumae.2025.501899","DOIUrl":"10.1016/j.reumae.2025.501899","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigated the association between high-altitude residence (>2500<!--> <!-->m above sea level) and the presence of high probability of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc).</div></div><div><h3>Methods</h3><div>A retrospective case–control study was conducted with 368 patients diagnosed with SSc at the rheumatology outpatient clinic of a university hospital in Bogotá, Colombia. Patients were divided into two groups based on the presence of high probability of PH. Clinical, demographic, and high-altitude residence data were collected and analyzed. A multiple logistic regression model was used to control confounding variables.</div></div><div><h3>Results</h3><div>Patients residing at high altitudes had a significantly greater risk of presenting high probability of PH than those living at lower altitudes did (odds ratio: 2.0). Other significant factors included the diffuse cutaneous subtype of SSc and the presence of interstitial lung disease.</div></div><div><h3>Discussion</h3><div>High-altitude residence is a potential risk factor for presenting high probability of PH in SSc patients, warranting closer monitoring and tailored management in these populations. Further studies are warranted to confirm these findings.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 6","pages":"Article 501899"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01DOI: 10.1016/j.reumae.2025.501892
Juan D. Cañete , Petra Díaz del Campo Fontecha , on behalf of the ESPOGUÍA Development Group
The important advances in the area of therapeutic interventions and the time elapsed have justified the complete update of the Clinical practice guideline on the treatment of axial spondyloarthritis and psoriatic arthritis (ESPOGUIA2017). Methodologically, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system has been incorporated, which allows the quality or certainty of the evidence to be assessed for each outcome of interest, previously prioritized by the drafting group and which structures the process of formulating recommendations explicitly. Thus, an updated clinical practice guideline has been developed to serve as a reference in the management of spondyloarthritis, to contribute to reduce unjustified variability, and to reinforce the importance of bringing clinical practice closer to the best available scientific evidence.
{"title":"Clinical practice guideline on the treatment of axial spondyloarthritis and psoriatic arthritis. ESPOGUÍA 2024","authors":"Juan D. Cañete , Petra Díaz del Campo Fontecha , on behalf of the ESPOGUÍA Development Group","doi":"10.1016/j.reumae.2025.501892","DOIUrl":"10.1016/j.reumae.2025.501892","url":null,"abstract":"<div><div>The important advances in the area of therapeutic interventions and the time elapsed have justified the complete update of the Clinical practice guideline on the treatment of axial spondyloarthritis and psoriatic arthritis (ESPOGUIA2017). Methodologically, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system has been incorporated, which allows the quality or certainty of the evidence to be assessed for each outcome of interest, previously prioritized by the drafting group and which structures the process of formulating recommendations explicitly. Thus, an updated clinical practice guideline has been developed to serve as a reference in the management of spondyloarthritis, to contribute to reduce unjustified variability, and to reinforce the importance of bringing clinical practice closer to the best available scientific evidence.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 6","pages":"Article 501892"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144791069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501896
Georgina Aguilera Barragán-Pickens , David Herrera van-Oostdam , Fedra Irazoque-Palazuelos , Miguel Saavedra-Salinas , Sergio Cerpa-Cruz , Claudia Mendoza-Pinto , Luis Valdez , Enrique Cuevas Orta , Eva Santillán-Guerrero , Carlos Abud-Mendoza , LUNPOS GROUP
Introduction
lupus nephritis represents a challenge in treatment. In spite of intensive therapy, is common a sustained renal incomplete response.
Objective
To describe different responses to adequate/intensive treatment to lupus nephritis.
Methods
Observational retrospective study, including Mexican > 18 years old patients with lupus nephritis who visited tertiary rheumatology centers in several urban cities in Mexico. SLE was diagnosed according to 1997 ACR. The exclusion criteria were follow-up < 6 months and reduced GFR due to other comorbidities such as diabetes or other primary renal disease.
Results
We included 193 patients with a mean age of 34 years, 80% were women. Biopsy was available in 166 patients (86%): class IV in 42%, class III in 23%, the mean of activity and chronicity index were 6.4 and 2.6 respectively; class V represented 10.2%. The least frequent class was Class II (9%), and mixed classes (III or IV + V) accounted for 11%.
Cyclophosphamide (CYC) was used in 146 patients (76.6%), mycophenolate (MMF) in 144 and tacrolimus (TCR) in 28. In most cases, were used combination therapy.
Only 38 patients had a follow-up of less than 1 year; 16 (42%) had CR, 13 (34%) had NR, and 9 (23%) PR. 55% of patients with PR received a multitarget protocol, 75% of CR received the NIH protocol, and 61.5% of NR the NIH protocol.
Of patients followed up for more than a year (155), 35% had persistently inactive response, 24.5% were relapsing–remitting, 20% were chronically active, and 20% showed a mixed pattern.
Conclusions
Prevalence of persistent or intermittent activity patterns was high (64.5%). Most Mexican rheumatologists switched to more intensive treatment, adding a second or third drug.
{"title":"Lupus nephritis in Mexican patients: Response to intensive therapy","authors":"Georgina Aguilera Barragán-Pickens , David Herrera van-Oostdam , Fedra Irazoque-Palazuelos , Miguel Saavedra-Salinas , Sergio Cerpa-Cruz , Claudia Mendoza-Pinto , Luis Valdez , Enrique Cuevas Orta , Eva Santillán-Guerrero , Carlos Abud-Mendoza , LUNPOS GROUP","doi":"10.1016/j.reumae.2025.501896","DOIUrl":"10.1016/j.reumae.2025.501896","url":null,"abstract":"<div><h3>Introduction</h3><div>lupus nephritis represents a challenge in treatment. In spite of intensive therapy, is common a sustained renal incomplete response.</div></div><div><h3>Objective</h3><div>To describe different responses to adequate/intensive treatment to lupus nephritis.</div></div><div><h3>Methods</h3><div>Observational retrospective study, including Mexican<!--> <!-->><!--> <!-->18 years old patients with lupus nephritis who visited tertiary rheumatology centers in several urban cities in Mexico. SLE was diagnosed according to 1997 ACR. The exclusion criteria were follow-up<!--> <!--><<!--> <!-->6 months and reduced GFR due to other comorbidities such as diabetes or other primary renal disease.</div></div><div><h3>Results</h3><div>We included 193 patients with a mean age of 34 years, 80% were women. Biopsy was available in 166 patients (86%): class IV in 42%, class III in 23%, the mean of activity and chronicity index were 6.4 and 2.6 respectively; class V represented 10.2%. The least frequent class was Class II (9%), and mixed classes (III or IV<!--> <!-->+<!--> <!-->V) accounted for 11%.</div><div>Cyclophosphamide (CYC) was used in 146 patients (76.6%), mycophenolate (MMF) in 144 and tacrolimus (TCR) in 28. In most cases, were used combination therapy.</div><div>Only 38 patients had a follow-up of less than 1 year; 16 (42%) had CR, 13 (34%) had NR, and 9 (23%) PR. 55% of patients with PR received a multitarget protocol, 75% of CR received the NIH protocol, and 61.5% of NR the NIH protocol.</div><div>Of patients followed up for more than a year (155), 35% had persistently inactive response, 24.5% were relapsing–remitting, 20% were chronically active, and 20% showed a mixed pattern.</div></div><div><h3>Conclusions</h3><div>Prevalence of persistent or intermittent activity patterns was high (64.5%). Most Mexican rheumatologists switched to more intensive treatment, adding a second or third drug.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501896"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501891
Raul E. Ruiz-Lozano , Luis Arnaldo Prida-Espaillat , Reinaldo A. Moll-Auais , Eugenia M. Ramos-Dávila , Manuel E. Quiroga-Garza , Aaron Zhao , Ali Khodor , Amr Almobayed , David Vega-Morales , Alejandro Rodriguez-Garcia
Purpose
This review emphasizes the significance of clinical findings, pathogenic mechanisms, diagnosis, management, and complications related to the ocular manifestations of rheumatoid arthritis, underscoring the need for interdisciplinary collaboration between rheumatologists and ophthalmologists.
Methods
A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Google Scholar for all English-language articles published from inception to July 2024. The following search string was utilized: (“rheumatoid arthritis”) AND (“dry eye disease” OR “dry eye” OR “episcleritis” OR “scleritis” OR “peripheral ulcerative keratitis” OR “central corneal ulcer*” OR “paracentral corneal ulcer*” OR “ocular manifestations” OR “ocular involvement”). Letters to the editor, editorials, short communications, case reports, case series, review articles, and original articles were reviewed, along with relevant references from those publications.
Results
The most common ocular manifestations in patients with rheumatoid arthritis include keratoconjunctivitis sicca (dry eye disease), episcleritis, scleritis, peripheral ulcerative keratitis, and central and paracentral corneal ulceration. Ocular involvement can be the initial presentation of the disease and may correlate with disease activity. If left untreated, ocular inflammation in rheumatoid arthritis can lead to permanent vision loss.
Conclusions
The diverse ocular inflammatory manifestations in RA patients may indicate either the disease's initial presentation or the status of extra-articular activity. A multidisciplinary approach that includes rheumatologists and ophthalmologists is essential to prevent sight-threatening complications.
目的综述类风湿关节炎眼部表现的临床表现、发病机制、诊断、治疗和并发症的重要性，强调风湿病学家和眼科医生之间跨学科合作的必要性。方法利用PubMed、Embase、Web of Science、b谷歌Scholar等数据库对自成立以来至2024年7月发表的所有英文论文进行综合文献检索。使用以下搜索字符串：（“类风湿性关节炎”）和（“干眼病”或“干眼”或“外巩膜炎”或“巩膜炎”或“周围性溃疡性角膜炎”或“中央性角膜溃疡*”或“中央旁性角膜溃疡*”或“眼部表现”或“眼部受累”）。审查了给编辑的信、社论、简短通讯、病例报告、病例系列、评论文章和原始文章，以及这些出版物的相关参考文献。结果类风湿性关节炎患者最常见的眼部表现为干眼病、表皮炎、巩膜炎、周围性溃疡性角膜炎、中央和中央旁性角膜溃疡。眼部受累可能是疾病的最初表现，并可能与疾病活动有关。如果不及时治疗，类风湿性关节炎引起的眼部炎症会导致永久性视力丧失。结论RA患者不同的眼部炎症表现可能表明疾病的初始表现或关节外活动的状态。包括风湿病学家和眼科医生在内的多学科方法对于预防威胁视力的并发症至关重要。
{"title":"Ocular inflammatory manifestations in patients with rheumatoid arthritis","authors":"Raul E. Ruiz-Lozano , Luis Arnaldo Prida-Espaillat , Reinaldo A. Moll-Auais , Eugenia M. Ramos-Dávila , Manuel E. Quiroga-Garza , Aaron Zhao , Ali Khodor , Amr Almobayed , David Vega-Morales , Alejandro Rodriguez-Garcia","doi":"10.1016/j.reumae.2025.501891","DOIUrl":"10.1016/j.reumae.2025.501891","url":null,"abstract":"<div><h3>Purpose</h3><div>This review emphasizes the significance of clinical findings, pathogenic mechanisms, diagnosis, management, and complications related to the ocular manifestations of rheumatoid arthritis, underscoring the need for interdisciplinary collaboration between rheumatologists and ophthalmologists.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Google Scholar for all English-language articles published from inception to July 2024. The following search string was utilized: (“rheumatoid arthritis”) AND (“dry eye disease” OR “dry eye” OR “episcleritis” OR “scleritis” OR “peripheral ulcerative keratitis” OR “central corneal ulcer*” OR “paracentral corneal ulcer*” OR “ocular manifestations” OR “ocular involvement”). Letters to the editor, editorials, short communications, case reports, case series, review articles, and original articles were reviewed, along with relevant references from those publications.</div></div><div><h3>Results</h3><div>The most common ocular manifestations in patients with rheumatoid arthritis include keratoconjunctivitis sicca (dry eye disease), episcleritis, scleritis, peripheral ulcerative keratitis, and central and paracentral corneal ulceration. Ocular involvement can be the initial presentation of the disease and may correlate with disease activity. If left untreated, ocular inflammation in rheumatoid arthritis can lead to permanent vision loss.</div></div><div><h3>Conclusions</h3><div>The diverse ocular inflammatory manifestations in RA patients may indicate either the disease's initial presentation or the status of extra-articular activity. A multidisciplinary approach that includes rheumatologists and ophthalmologists is essential to prevent sight-threatening complications.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501891"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501894
Francisco Javier Olmedo Garzón
In line with vascular hypothesis of systemic sclerosis (SSc), it is proposed that visceral Raynaud's phenomenon (RP)/endothelial dysfunction causes severe oxygen supply/consumption imbalance in internal organs, leading to visceral ischemic failure in early SSc, especially with cold environmental temperature (Te) and severe RP. There would also be a decrease in body thermogenesis and a decrease in heat loss caused by chronic visceral ischemia and by systemic vasculopathy, respectively. At any given time, these disorders could produce low core temperature (Tc). Hence, SSc is proposed as a candidate cause of secondary hypothermia. It is suggested that SSc could be an adaptive response in cold Te to systemic endothelial damage with secondary chronic visceral ischemia/slow metabolism. This pathophysiological mechanism is proposed in early visceral failure, prognosis, SSc phenotype according to ethnicity, and other manifestations. The impact of Te and Tc on SSc warrants further investigations.
根据系统性硬化血管假说（vascular hypothesis of systemic sclerosis, SSc），提出内脏雷诺现象（内脏Raynaud's phenomenon， RP）/内皮功能障碍导致内脏供氧/消耗严重失衡，导致SSc早期内脏缺血性衰竭，尤其是环境温度较低（Te）和严重的RP。慢性内脏缺血和全身性血管病变也会导致机体产热减少和热损失减少。在任何给定时间，这些紊乱都可能产生较低的堆芯温度（Tc）。因此，SSc被认为是继发性体温过低的一个候选原因。提示SSc可能是低温Te对继发性慢性内脏缺血/代谢缓慢的全身内皮损伤的适应性反应。这种病理生理机制在早期内脏衰竭、预后、SSc种族表型和其他表现中被提出。Te和Tc对SSc的影响值得进一步研究。
{"title":"Some aspects of body thermoregulation, environmental temperature and vascular hypothesis in systemic sclerosis patients","authors":"Francisco Javier Olmedo Garzón","doi":"10.1016/j.reumae.2025.501894","DOIUrl":"10.1016/j.reumae.2025.501894","url":null,"abstract":"<div><div>In line with vascular hypothesis of systemic sclerosis (SSc), it is proposed that visceral Raynaud's phenomenon (RP)/endothelial dysfunction causes severe oxygen supply/consumption imbalance in internal organs, leading to visceral ischemic failure in early SSc, especially with cold environmental temperature (Te) and severe RP. There would also be a decrease in body thermogenesis and a decrease in heat loss caused by chronic visceral ischemia and by systemic vasculopathy, respectively. At any given time, these disorders could produce low core temperature (Tc). Hence, SSc is proposed as a candidate cause of secondary hypothermia. It is suggested that SSc could be an adaptive response in cold Te to systemic endothelial damage with secondary chronic visceral ischemia/slow metabolism. This pathophysiological mechanism is proposed in early visceral failure, prognosis, SSc phenotype according to ethnicity, and other manifestations. The impact of Te and Tc on SSc warrants further investigations.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501894"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501872
Clementina López-Medina , Lucía Otero-Varela , Fernando Sánchez-Alonso , Vega Jovaní , Lorena Expósito-Pérez , Sheila Melchor-Díaz , Yanira Pérez-Vera , Paula Pretel-Ruiz , Javier Manero , Antonio Mera-Varela , Lourdes Mateo , Dolores Ruiz-Montesino , José Andrés Lorenzo-Martín , Teresa Pedraz-Penalva , Isabel Castrejón
Introduction
Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.
Method
Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.
Results
A total of 335 patients ever exposed to IXE were included (PsA = 250; axSpA = 85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.
Conclusions
In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.
ixekizumab （ixxe）是一种选择性白细胞介素17A （IL-17A）单克隆抗体，被批准用于治疗银屑病关节炎（PsA）和轴性脊柱炎（axSpA）。关于其留存率和有效性的真实数据有限。本研究的目的是评估现实世界axSpA和PsA患者中IXE的1年保留率，并确定药物保留率的潜在预测因素。方法：前瞻性和观察性研究来源于BIOBADASER 3.0，这是一个多中心的先进治疗注册，包括曾因PsA或axSpA接受IXE治疗的患者。采用Kaplan-Meier曲线和多变量Cox回归评估两种疾病治疗的1年保留率。结果共纳入335例暴露于IXE的患者(PsA = 250；axSpA = 85)。仅5.3%的患者使用IXE作为一线治疗，而在TNFi后使用IXE的患者比例为94.7%。在axSpA和PsA中，12个月的药物生存率为69.5% (95% CI 64.0-74.3), PsA (71.3% （95% CI 65.0-75.6）略高于axSpA （63.8% (95% CI 51.5-73.7)）。多变量Cox回归模型显示，在整个人群中，女性和较长的病程是IXE停药的相关因素，而同时使用甲氨蝶呤降低了停药的风险。在这项现实世界的研究中，IXE在PsA和axSpA患者中随访1年后显示出可接受的保留率。女性和较长的疾病持续时间与停药风险相关。
{"title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry","authors":"Clementina López-Medina , Lucía Otero-Varela , Fernando Sánchez-Alonso , Vega Jovaní , Lorena Expósito-Pérez , Sheila Melchor-Díaz , Yanira Pérez-Vera , Paula Pretel-Ruiz , Javier Manero , Antonio Mera-Varela , Lourdes Mateo , Dolores Ruiz-Montesino , José Andrés Lorenzo-Martín , Teresa Pedraz-Penalva , Isabel Castrejón","doi":"10.1016/j.reumae.2025.501872","DOIUrl":"10.1016/j.reumae.2025.501872","url":null,"abstract":"<div><h3>Introduction</h3><div>Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.</div></div><div><h3>Method</h3><div>Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.</div></div><div><h3>Results</h3><div>A total of 335 patients ever exposed to IXE were included (PsA<!--> <!-->=<!--> <!-->250; axSpA<!--> <!-->=<!--> <!-->85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501872"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501897
Aurora González Murcia , Isabel Valencia Ramírez , Teresa Catalina Plaza Aguado , José Antonio González Ferrández
We present the case of a 42-year-old male patient who was admitted for the study of axial and pelvic girdle pain, being diagnosed with hypophosphatemic osteomalacia secondary to a mesenchymal tumour after ruling out other causes of osteomalacia.
{"title":"Hypophosphatemic osteomalacia secondary to mesenchymal tumor","authors":"Aurora González Murcia , Isabel Valencia Ramírez , Teresa Catalina Plaza Aguado , José Antonio González Ferrández","doi":"10.1016/j.reumae.2025.501897","DOIUrl":"10.1016/j.reumae.2025.501897","url":null,"abstract":"<div><div>We present the case of a 42-year-old male patient who was admitted for the study of axial and pelvic girdle pain, being diagnosed with hypophosphatemic osteomalacia secondary to a mesenchymal tumour after ruling out other causes of osteomalacia.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501897"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号